Osteoarthritis and gouty arthritis

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

Loading Image

Finding Sources

Reading File

Loading Image

I now have comprehensive information from the textbook. Let me compile a thorough answer.

Osteoarthritis and Gouty Arthritis

OSTEOARTHRITIS (OA)

Definition & Overview

Osteoarthritis (also called degenerative joint disease) is a disorder characterized by degeneration of articular cartilage resulting in structural and functional failure of synovial joints. It is the most common disease of joints. Despite the "-itis" suffix, it is primarily a degenerative disorder - inflammation is secondary, not primary.

Primary (idiopathic) OA: ~95% of cases; appears insidiously as an aging phenomenon; oligoarticular; affects weight-bearing joints
Secondary OA: ~5% of cases; arises in younger individuals from joint deformity, prior injury, or systemic disease (diabetes, obesity)
Prevalence increases exponentially after age 50; ~40% of people over 70 are affected

Pathogenesis

Biomechanical stress is the principal mechanism. Genetic factors (polymorphisms in matrix and signaling genes) also contribute. The sequence of events:

FIG. 19.31 - Stages of OA: (1) Chondrocyte injury, (2) Early OA with degradation exceeding repair, (3) Late OA with chondrocyte loss and subchondral bone damage.

Chondrocyte injury - from biomechanical stress, in a genetically predisposed patient
Early OA - chondrocytes proliferate and attempt repair, but release MMPs (matrix metalloproteinases) that degrade collagen and proteoglycans. Inflammatory mediators (PGE2, NO, TNF) perpetuate damage. TGF-β attempts counter-regulation but is overwhelmed.
Late OA - chondrocyte dropout (apoptosis), full-thickness cartilage loss, subchondral bone changes, osteophyte formation at articular margins

Key molecular mediators include:

Degradative: MMPs, aggrecanases, PGE2, nitric oxide, TNF, IL-1
Reparative (inadequate): TGF-β, BMP (bone morphogenetic protein)

Morphology

Advanced OA shows:

Fibrillation and loss of articular cartilage - cartilage becomes frayed, vertical clefts form
Loose bodies ("joint mice") - fragments of dislodged cartilage and subchondral bone in the joint space
Bone eburnation - exposed subchondral bone is polished ivory-like from friction
Subchondral cysts - synovial fluid forced into bone through fracture gaps via a ball-valve mechanism
Osteophytes - bony outgrowths at articular margins, capped by fibrocartilage, that gradually ossify
Mild synovitis - congested, fibrotic synovium with scattered chronic inflammatory cells (minimal, unlike RA)

OA histology showing fibrillated cartilage (A) and eburnated subchondral bone (B)

FIG. 19.32 - (A) Fibrillation of articular cartilage. (B) Eburnated articular surface showing: (1) exposed subchondral bone, (2) subchondral cyst, (3) residual articular cartilage.

Clinical Features

Typically presents in patients in their 50s+; if younger, search for an underlying cause
Symptoms: joint pain worsening with use, morning stiffness (brief, <30 min), crepitus, limited range of motion
Osteophytes on spine - compress cervical/lumbar nerve roots → radicular pain, muscle spasms, atrophy, neurologic deficits
Joints involved: hips, knees, lower lumbar and cervical vertebrae, proximal and distal interphalangeal (PIP/DIP) finger joints, first carpometacarpal joints, first tarsometatarsal joints
Heberden nodes - osteophytes at DIP joints; more common in women
Bouchard nodes - osteophytes at PIP joints
No joint fusion (unlike RA)
Radiographic severity does not correlate well with pain and disability

Treatment

Pain management (acetaminophen, NSAIDs to reduce inflammation)
Intra-articular corticosteroids
Activity modification, weight loss
Joint replacement for severe cases
No disease-modifying therapy currently prevents or halts OA progression

GOUTY ARTHRITIS

Definition & Overview

Gout is characterized by transient attacks of acute arthritis initiated by monosodium urate (MSU) crystals deposited within and around joints. It is driven by hyperuricemia (plasma urate >6.8 mg/dL), which is necessary but not sufficient for gout to develop.

Primary gout: ~90% of cases; most commonly due to reduced renal excretion of uric acid (cause usually unknown)
Secondary gout: ~10%; due to identifiable causes of hyperuricemia

Pathogenesis of Hyperuricemia

Uric acid is the final end-product of purine catabolism in humans (we lack uricase). Sources of excess urate:

Overproduction:

Increased purine synthesis via the de novo pathway or salvage pathway defects
Partial HGPRT (hypoxanthine guanine phosphoribosyltransferase) deficiency - interrupts the salvage pathway
Complete HGPRT absence = Lesch-Nyhan syndrome (severe neurologic manifestations dominate)
Rapid cell lysis (tumor lysis syndrome from chemotherapy)

Underexcretion:

Uric acid is normally filtered by the glomerulus, then almost completely reabsorbed by the proximal tubule, with a small fraction secreted by the distal nephron
Reduced distal secretion is the basis of primary gout in most patients
Chronic renal disease reduces excretion

Other contributing factors (beyond hyperuricemia):

Age and duration of hyperuricemia (gout usually appears after 20-30 years of sustained hyperuricemia)
Alcohol consumption (increases urate production and impairs excretion)
Diet high in purines (red meat, shellfish)
Only ~10% of hyperuricemic individuals ever develop gout

Mechanism of Joint Inflammation

Once MSU crystals precipitate in the joint:

Resident synovial macrophages phagocytose urate crystals
Crystals activate the cytosolic NLRP3 inflammasome
Inflammasome activates caspase-1 → cleaves pro-IL-1β into active IL-1β
IL-1β recruits and activates neutrophils into the joint
Neutrophils release cytokines, free radicals, and proteases
Crystals also rupture phagolysosomal membranes → lysosomal enzyme leakage
Result: intense acute inflammatory arthritis, which typically remits spontaneously in days to weeks

Morphology

Acute gouty arthritis:

Intense neutrophilic infiltrate in synovium and synovial fluid
MSU crystals in neutrophil cytoplasm - long, slender, needle-shaped, negatively birefringent under polarized light
Synovium is edematous and congested

Chronic tophaceous arthritis:

Repeated attacks → urate crystals encrust the articular surface
Pannus (hyperplastic, fibrotic, inflamed synovium) destroys underlying cartilage
Tophi (pathognomonic of gout) - large aggregates of urate crystals in synovial membranes, articular cartilage, ligaments, tendons, and bursae; surrounded by foreign body giant cell reaction

Gouty nephropathy:

Uric acid nephrolithiasis (kidney stones)
Urate tophi in renal medullary interstitium/tubules → pyelonephritis risk

FIG. 19.40 - (A) Amputated great toe with tophi (red arrows) involving joint and soft tissues. (B) Gouty tophus: dissolved urate crystals surrounded by reactive fibroblasts, mononuclear cells, and giant cells (H&E). (C) Needle-shaped, negatively birefringent urate crystals under polarized light.

Clinical Stages (Four Recognized Stages)

Stage	Features
1. Asymptomatic hyperuricemia	Begins around puberty in men, after menopause in women; no symptoms
2. Acute gouty arthritis	Sudden, excruciating monoarticular pain; localized hyperemia and warmth; 50% first attacks involve the 1st metatarsophalangeal (MTP) joint (podagra); self-resolving in hours to weeks without treatment
3. Intercritical period	Symptom-free interval between attacks; without treatment, attacks recur more frequently and become polyarticular
4. Chronic tophaceous gout	Develops ~10 years after first attack; juxtaarticular bone erosion, joint space loss, tophi visible in soft tissues

Diagnosis

The gold standard is aspiration of synovial fluid (or tophus material) and identification of needle-shaped, negatively birefringent crystals under polarized light microscopy. Serum uric acid >6.8 mg/dL supports the diagnosis but is neither sensitive nor specific during an acute attack.

Treatment

Goal	Agents
Acute attack - anti-inflammatory	NSAIDs (indomethacin), colchicine, systemic corticosteroids
Urate-lowering - reduce production	Xanthine oxidase inhibitors: allopurinol, febuxostat
Urate-lowering - increase excretion	Uricosuric drugs: probenecid, benzbromarone
Lifestyle modification	Weight loss, reduce alcohol, reduce dietary purines (red meat, organ meats, shellfish)

Gout generally does not shorten life span but significantly affects quality of life.

Key Comparison: OA vs. Gouty Arthritis

Feature	Osteoarthritis	Gouty Arthritis
Mechanism	Mechanical cartilage degeneration	Urate crystal-induced inflammation
Inflammation	Secondary/mild	Primary/intense (neutrophilic)
Demographics	Elderly; both sexes	Middle-aged men; post-menopausal women
Joint distribution	Weight-bearing + DIP/PIP fingers	1st MTP joint (podagra); later polyarticular
Onset	Gradual, chronic	Sudden, episodic acute attacks
Crystal finding	None	MSU crystals - needle-shaped, negatively birefringent
Pathognomonic lesion	Osteophytes, bone eburnation	Tophi
Serology	Negative	Hyperuricemia (serum urate >6.8 mg/dL)
Joint fusion	No	No
Systemic involvement	No	Renal (nephrolithiasis, nephropathy)

Comparison of OA vs RA morphology (OA features highlighted on right)

FIG. 19.33 - Joint morphology comparison. The OA panel (right) shows the classic features: osteophytes, loose bodies, thinned fibrillated cartilage, subchondral sclerosis and cysts, and only mild synovial inflammation - with no ankylosis.

Sources: Robbins & Kumar Basic Pathology, 10th ed., Chapter 19 (Joint Diseases)

This is a shared conversation. Sign in to Orris to start your own chat.